FIT kit colonoscopy plea


People who return tests after using pharmacy bowel screening kits should be able to get direct access to publicly funded colonoscopies through their general practitioners, Bowel Cancer New Zealand says.

The organisation is concerned people are being denied public colonoscopies, despite it taking more blood in the sample to trigger a positive result using the pharmacy kit than that required to prompt referral for a colonoscopy in the national screening programme (see fact box).

Recently, The Star featured Brighton man Michael Horgan, who was denied a public colonoscopy at the Southern District Health Board following a GP referral after the over-the-counter faecal immunochemical test (FIT) he completed returned a positive result.

He went on to have a private colonoscopy and a tumour was detected.

Mr Horgan has since been cleared of his cancer and life is back to normal for him.

He said he agreed with Bowel Cancer New Zealand that there should be publicly funded colonoscopies for positive pharmacy tests.

Anyone who returned a similar result when participating in the national programme, to be introduced in the Southern District Health board area next month, would be offered a publicly funded colonoscopy.

“It reflects very poorly on our public health system. Many lives could potentially be saved if those who received a positive test for the pharmacy kit were able to have a colonoscopy through the public health system,” Mr Horgan said.

He would like the threshold for publicly funded colonoscopy to be the same, regardless of whether results were from public screening or the pharmacy test kits, he said.

He also said there appeared to be more publicity for breast and prostate cancer screening than bowel cancer, despite bowel cancer killing more New Zealanders than breast and prostate cancer combined.

Bowel Cancer NZ executive member Sarah Derrett said the response to GP referrals after patients had returned positive FIT tests, outside the official screening programme, seemed to vary between DHBs.

The national criteria for direct access to publicly funded colonoscopies say that use of faecal occult blood tests collected in asymptomatic individuals is not recommended in New Zealand at present (outside the Waitemata District Health Board bowel screening pilot) and should not be encouraged.

Cancer Society medical director and oncologist Chris Jackson said the situation was complex.

The pharmacy bowel screening kit test did not take personal circumstances, family history, personal history or symptoms into account, therefore “we believe that isn’t the right way of going about screening individuals worried about bowel cancer”.

Blood found in faeces could be related to conditions other than bowel cancer.

Dr Jackson said someone with a positive pharmacy test could still be referred to a specialist for review and discussion and could get a colonoscopy as a result of that discussion.

“They may have other testing if more appropriate.”

The direct-access guidelines were an attempt to set a “likelihood threshold” for colonoscopy.

“If your risk of cancer was considered above ‘X’ then you would get a colonoscopy; if it was below ‘X’, you would not.

“The debate should be focused on the accuracy and sustainable threshold for that ‘X’, and the resourcing and quality control to deliver sufficient colonoscopies to achieve that,” Dr Jackson said.

Questions posed to the Ministry of Health concerning the guidelines and whether someone returning a positive test could still be regarded as asymptomatic, have yet to be answered through the ministry’s formal Official Information Act process.

Bowel Cancer NZ collaborated with Bowel Screen Australia and Green Cross Health to introduce the BowelScreen Aotearoa kits several years ago.

Its website states it does not receive any financial benefit or otherwise from the test kit initiative.

Faecal immunochemical test (FIT) thresholds – the amount of blood in faeces which would return a positive test:

National bowel screening programme: 40ug haemoglobin/gram dried faeces (or 200ng Hb/ml buffer solution)

Waitemata pilot programme: 15ug/ Hb/g (75ng Hb/ml buffer)

BowelScreen Aotearoa (pharmacy kit): 50ug/Hb/g (250ng Hb/ml buffer)

ug = a microgram, which is one millionth of a gram or one thousandth of a milligram.

ng = A nanogram, which is equal to one billionth of a gram